Omeros Corporation (OMER)
Omeros stock crashes on regulatory setback: buy the dip?
Omeros Corp (OMER) stock is tumbling on Friday morning following a major regulatory setback in Europe that has caught investors off guard. Investors are bailing on OMER mostly because the European Medicines Agency's (EMA) expert panel has rejected its primary commercial asset.
Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now
Omeros (OMER) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Omeros Q1 Earnings Call Highlights
Omeros NASDAQ: OMER reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA.
Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript
Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript
Here's Why Omeros (OMER) is a Great Momentum Stock to Buy
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade
The consensus price target hints at a 222.8% upside potential for Omeros (OMER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 266.7% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript
Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript
Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript
Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript
Omeros prices transplant complication drug at $36,000 per dose
Omeros will price its recently approved drug for a life-threatening transplant complication in adults and children aged two and older at $36,000 per single-dose vial, CEO Gregory Demopulos said on a call with analysts on Wednesday.
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA
OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.
Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely
Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation. Yartemlea is the first and only approved therapy for TA-TMA, showing high complete response rates and strong survival benefits in pivotal trials. I estimate Yartemlea's peak revenue potential at ~$300m, with commercialization pacing dependent on awareness, funding, and OMER's ability to scale.
